Notice: This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends EDGE vs. PBH, PRGO, PTCT, ZLAB, RARE, OGN, RNA, RYTM, APLS, and MRUSShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Prestige Consumer Healthcare (PBH), Perrigo (PRGO), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Avidity Biosciences (RNA), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), and Merus (MRUS). These companies are all part of the "medical" sector. Edge Therapeutics vs. Prestige Consumer Healthcare Perrigo PTC Therapeutics Zai Lab Ultragenyx Pharmaceutical Organon & Co. Avidity Biosciences Rhythm Pharmaceuticals Apellis Pharmaceuticals Merus Edge Therapeutics (NASDAQ:EDGE) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Is EDGE or PBH more profitable? Prestige Consumer Healthcare has a net margin of 19.13% compared to Edge Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 12.36% beat Edge Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Prestige Consumer Healthcare 19.13%12.36%6.39% Do analysts rate EDGE or PBH? Prestige Consumer Healthcare has a consensus price target of $92.60, suggesting a potential upside of 11.80%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prestige Consumer Healthcare 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer EDGE or PBH? In the previous week, Prestige Consumer Healthcare had 10 more articles in the media than Edge Therapeutics. MarketBeat recorded 10 mentions for Prestige Consumer Healthcare and 0 mentions for Edge Therapeutics. Prestige Consumer Healthcare's average media sentiment score of 1.27 beat Edge Therapeutics' score of 0.00 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Overall Sentiment Edge Therapeutics Neutral Prestige Consumer Healthcare Positive Which has more risk and volatility, EDGE or PBH? Edge Therapeutics has a beta of 3.65, suggesting that its stock price is 265% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Do insiders & institutionals have more ownership in EDGE or PBH? 28.0% of Edge Therapeutics shares are held by institutional investors. Comparatively, 99.9% of Prestige Consumer Healthcare shares are held by institutional investors. 37.1% of Edge Therapeutics shares are held by company insiders. Comparatively, 1.6% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor EDGE or PBH? Prestige Consumer Healthcare received 318 more outperform votes than Edge Therapeutics when rated by MarketBeat users. Likewise, 70.41% of users gave Prestige Consumer Healthcare an outperform vote while only 66.79% of users gave Edge Therapeutics an outperform vote. CompanyUnderperformOutperformEdge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Prestige Consumer HealthcareOutperform Votes49570.41% Underperform Votes20829.59% Which has better earnings and valuation, EDGE or PBH? Prestige Consumer Healthcare has higher revenue and earnings than Edge Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/APrestige Consumer Healthcare$1.12B3.67$209.34M$4.2719.40 SummaryPrestige Consumer Healthcare beats Edge Therapeutics on 13 of the 15 factors compared between the two stocks. Remove Ads Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.16B$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E RatioN/A6.1223.7319.00Price / SalesN/A226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book38.706.656.904.26Net Income-$40.86M$139.34M$3.18B$247.00M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$36.77-0.8%N/A+647.0%$1.16BN/A0.00N/APBHPrestige Consumer Healthcare4.339 of 5 stars$85.67+1.7%$92.60+8.1%+14.2%$4.24B$1.12B20.06540Analyst DowngradeInsider TradeNews CoveragePositive NewsPRGOPerrigo4.8146 of 5 stars$29.50+0.7%$33.00+11.9%-8.8%$4.02B$4.37B-25.219,140Insider TradeShort Interest ↓PTCTPTC Therapeutics3.203 of 5 stars$51.93+0.3%$62.08+19.6%+71.3%$4.01B$806.78M-8.741,410Analyst UpgradeZLABZai Lab2.1079 of 5 stars$35.91+5.6%$40.05+11.5%+76.7%$3.93B$398.99M-12.962,175Gap DownHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3345 of 5 stars$40.87-0.6%$93.50+128.8%-21.0%$3.78B$560.23M-6.451,276OGNOrganon & Co.4.8619 of 5 stars$14.45+1.1%$20.80+44.0%-14.5%$3.72B$6.40B4.3410,000Positive NewsRNAAvidity Biosciences2.0798 of 5 stars$29.55+3.5%$65.20+120.6%+40.7%$3.53B$10.90M-10.26190Analyst ForecastNews CoverageGap UpRYTMRhythm Pharmaceuticals4.3352 of 5 stars$52.97-0.5%$69.08+30.4%+23.6%$3.26B$130.13M-12.23140APLSApellis Pharmaceuticals4.2425 of 5 stars$26.00+3.8%$45.53+75.1%-58.0%$3.23B$781.37M-12.81770Short Interest ↑MRUSMerus2.3016 of 5 stars$46.29+3.7%$85.77+85.3%-0.3%$3.17B$36.13M-11.7237Analyst Forecast Remove Ads Related Companies and Tools Related Companies Prestige Consumer Healthcare Competitors Perrigo Competitors PTC Therapeutics Competitors Zai Lab Competitors Ultragenyx Pharmaceutical Competitors Organon & Co. Competitors Avidity Biosciences Competitors Rhythm Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Merus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredTrump announces revenge on BidenA former CIA insider just made a stunning prediction: Trump’s revenge on Biden will end America’s energy cr...Paradigm Press | SponsoredMagnificent 7 wipeout: What's next?A massive wave of volatility is sweeping the stock market... After the recent selloff, the "Magnificent Sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
